Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology

Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo

(2017) Maiana Larsabal et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Targeted Agents: Management of Dermatologic Toxicities

(2017) Barbara Burtness   Journal of the National Comprehensive Cancer Network

Multikinase Inhibitor-Induced Hand–Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management

(2016) Kumutnart Chanprapaph et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Vemurafenib-Induced Neutrophilic Panniculitis

(2016) Igor Vázquez-Osorio et al.   AMERICAN JOURNAL OF DERMATOPATHOLOGY

Management of toxicities of immune checkpoint inhibitors

(2016) Lavinia Spain et al.   CANCER TREATMENT REVIEWS

Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus

(2016) Vincenza Conteduca et al.   Clinical Genitourinary Cancer

Diverse types of dermatologic toxicities from immune checkpoint blockade therapy

(2016) Jonathan L. Curry et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort

(2016) Shelley Ji Eun Hwang et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Anti-PD1-induced psoriasis: a study of 21 patients

(2016) J. Bonigen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies

(2016) Shelley J.E. Hwang et al.   MELANOMA RESEARCH

Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review

(2016) Hua Zheng et al.   Experimental and Therapeutic Medicine

Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management

(2015) B. McLellan et al.   ANNALS OF ONCOLOGY

Management of Dermatologic Complications of Lung Cancer Therapies

(2015) Silvina B. Pugliese et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Incidence and risk of xerosis with targeted anticancer therapies

(2015) Johannah Valentine et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Cutaneous adverse effects of targeted therapies

(2015) James B. Macdonald et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

RASopathic alopecia: Hair changes associated with vemurafenib therapy

(2015) Bianca Maria Piraccini et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Cutaneous adverse effects of targeted therapies

(2015) James B. Macdonald et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Drug-Associated Dermatomyositis Following Ipilimumab Therapy

(2015) Shirwa Sheik Ali et al.   JAMA Dermatology

Dermatological Toxicity Associated with Targeted Therapies in Cancer: Optimal Management

(2014) Lucie Peuvrel et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients

(2014) Tanusree Paul et al.   EUROPEAN JOURNAL OF CANCER

Case of vemurafenib-induced Sweet's syndrome

(2014) Jeffrey T. Yorio et al.   JOURNAL OF DERMATOLOGY

Management of Common Adverse Events in Patients Treated With Sorafenib: Nurse and Pharmacist Perspective

(2014) Christine M. Walko et al.   SEMINARS IN ONCOLOGY

Anomalies pigmentaires induites par les traitements anticancéreux. Deuxième partie : les thérapies ciblées

(2013) V. Sibaud et al.   ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE

Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors

(2013) R. Anforth et al.   BRITISH JOURNAL OF DERMATOLOGY

Pilot Clinical Trial on the Efficacy of Prophylactic Use of Vitamin K1–Based Cream (Vigorskin) to Prevent Cetuximab-Induced Skin Rash in Patients With Metastatic Colorectal Cancer

(2013) Francesco Pinta et al.   Clinical Colorectal Cancer

Vemurafenib: an unusual UVA-induced photosensitivity

(2013) Pauline Gelot et al.   EXPERIMENTAL DERMATOLOGY

Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis

(2013) Courtney J. Ensslin et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions

(2013) Herbert C. Chiang et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy

(2013) Sofya Pintova et al.   MELANOMA RESEARCH

Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma

(2013) M. E. Lacouture et al.   ONCOLOGIST

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

(2013) Caroline J. Voskens et al.   PLoS One

Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

(2013) Hong-bing Liu et al.   PLoS One

Prevention and management of adverse events related to regorafenib

(2013) Mieke De Wit et al.   SUPPORTIVE CARE IN CANCER

Tracking of Second Primary Melanomas in Vemurafenib-Treated Patients

(2013) Stephane Dalle et al.   JAMA Dermatology

Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its Management

(2012) Lisa Zimmer   ARCHIVES OF DERMATOLOGY

Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing SelectiveBRAFInhibition

(2012) Lisa Zimmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

(2012) Alice P. Chen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study

(2012) Emily Y. Chu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Cutaneous toxicities of RAF inhibitors

(2012) Rachael Anforth et al.   LANCET ONCOLOGY

Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials

(2012) Fausto Petrelli et al.   LUNG CANCER

Ultraviolet A and Photosensitivity during Vemurafenib Therapy

(2012) Reinhard Dummer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review

(2012) J.-B. Bachet et al.   ONCOLOGIST

Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study

(2012) Pascaline Boudou-Rouquette et al.   PLoS One

Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib

(2011) BETH MCLELLAN et al.   Dermatologic Therapy

Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission

(2011) Wouter V. Vogel et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

(2011) Mario E. Lacouture et al.   SUPPORTIVE CARE IN CANCER

Cicatrisation et thérapies ciblées : quelles précautions en période périopératoire ?

(2010) G. Pignot et al.   PROGRES EN UROLOGIE

Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy

(2009) R. E. Eilers et al.   JNCI-Journal of the National Cancer Institute

Search for Evidence-Based Approaches for the Prevention and Palliation of Hand-Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs)

(2009) R. Anderson et al.   ONCOLOGIST

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

(2009) Kamalesh Sankhala et al.   Targeted Oncology

Skin toxicities associated with epidermal growth factor receptor inhibitors

(2009) Tianhong Li et al.   Targeted Oncology

Skin toxicity caused by EGFR antagonists-An autoinflammatory condition triggered by deregulated IL-1 signaling?

(2008) Ulrich Rodeck   JOURNAL OF CELLULAR PHYSIOLOGY

Toxic erythema of chemotherapy: A useful clinical term

(2008) Jean L. Bolognia et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Imatinib-associated hyperpigmentation, a side effect that should be recognized

(2008) T Mcpherson et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib

(2008) S. E. Rosenbaum et al.   SUPPORTIVE CARE IN CANCER

Cutaneous Reactions Related to Systemic Immunomodulators and Targeted Therapeutics

(2007) Lisa A. Hammond-Thelin   DERMATOLOGIC CLINICS